Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lantern Pharma Inc. (LTRN)

Lantern Pharma hosts webinar on Open-Medicine AI platform for drug development

Neutral Impact 1 of 5 other Written later

On September 23, 2026, Lantern Pharma hosted a live webinar discussing its Open-Medicine AI multi-agentic platform for drug development. The filing is a Regulation FD disclosure that furnishes the presentation used in the webinar and provides a replay link, with no financial results or guidance included.

Key points

  • Webinar held September 23, 2026, covering the Open-Medicine AI multi-agentic platform for drug development
  • A webinar replay is available via a YouTube link and on the investors section of the company website
  • Presentation furnished as Exhibit 99.1 and incorporated by reference; the filing states it is not deemed filed under Section 18 of the Exchange Act

The filing

CompanyLantern Pharma Inc. (LTRN)
Form8-K, current report
Filed with the SECSep 23, 2026, 8:41 PM ET
Accession number0001493152-26-044007

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.